Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity
Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and might consider partnering them for certain indications.
You may also be interested in...
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.